News

Back

ReiThera, LEUKOCARE and Univercells announce pan-European consortium for the fast-track development of a single-dose adenovirus-based COVID-19 vaccine

April 23rd 2020

BioPark

Italian ReiThera Srl. (Rome), German LEUKOCARE AG (Munich), and Belgian Univercells S.A. (Brussels), today announced a strategic collaboration for the development and largescale manufacturing of a novel adenoviral vector-based vaccine against COVID-19. The vaccine candidate is expected to enter clinical trials during summer 2020 with largescale vaccine production planned to start soon after. The partners will contribute to the program combining their individual strengths and expertise to accelerate the development of the vaccine. In support of the fight against a long-lasting pandemic outbreak, the three European biotech companies have formed a pan-European consortium to pursue this strategy and develop a single-dose vaccine. Please discover the press release here.